✦ LIBER ✦

Irinotecan in 5-Fluorouracil—Refractory Colorectal Cancer

✍ Scribed by Romano Danesi; Antonello Di Paolo

Book ID: 119616972
Publisher: CIG Media Group, LP.
Year: 2002
Tongue: English
Weight: 53 KB
Volume: 2
Category: Article
ISSN: 1533-0028
DOI: 10.1016/s1533-0028(11)70512-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Palliative Benefit of Irinotecan in

The Palliative Benefit of Irinotecan in 5-Fluorouracil—Refractory Colorectal Cancer: Its Prospective Evaluation by a Multicenter Canadian Trial

✍ M. Michael; D. Hedley; A. Oza; R. Feld; M. Pintilie; R. Goel; J. Maroun; J. Joli 📂 Article 📅 2002 🏛 CIG Media Group, LP. 🌐 English ⚖ 139 KB

Hyaluronan-Irinotecan improves progressi

Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial

✍ Peter Gibbs; Philip R. Clingan; Vinod Ganju; Andrew H. Strickland; Shirley S. Wo 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 459 KB

Irinotecan (CPT-11) as first-line monoth

Irinotecan (CPT-11) as first-line monotherapy in patients with advanced, metastatic colorectal cancer refractory to 5-fluorouracil adjuvant chemotherapy: a multicenter phase II study

✍ Matilde Navarro García; Ferrán Losa Gaspa; Hermini Manzano Alemany; Pilar García 📂 Article 📅 2002 🏛 Springer Milan 🌐 Spanish ⚖ 148 KB

Bevacizumab in association with de Gramo

Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer : A single-center phase 2 trial

✍ Bruno Vincenzi; Daniele Santini; Antonio Russo; Chiara Spoto; Olga Venditti; Sim 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

## Abstract ## BACKGROUND: The aim of the current study was the investigation of the value of bevacizumab + 5‐fluorouracil(5–FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options. ## METHODS: The authors included 48 heavily pretreated pati

242 Phase I study of irinotecan (I), ral

242 Phase I study of irinotecan (I), raltitrexed (R), and 5-fluorouracil (5FU) in the treatment of metastatic colorectal cancer (MCRC) refractory to thymidylate synthase inhibitors (TSI)

✍ R. Goel; J. Maroun; C. Cripps; D. Jonker; G. Chiritescu; S. Dahrouge; L. Douglas 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 165 KB

Irinotecan and 5-Fluorouracil in colorec

Irinotecan and 5-Fluorouracil in colorectal cancer: time for a pause?

✍ V.R Bulusu 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 97 KB